Table 2 Basic information of the patients
From: Efficacy analysis of intraoperative radiotherapy in patients with early-stage breast cancer
Items | Number of cases (%) |
|---|---|
Age (years) | |
Group 1: 40–49 | 15 (20.5) |
Group 2: 50–59 | 20 (27.4) |
Group 3: 60–69 | 27 (37.0) |
Group 4: ≥ 70 | 11 (15.1) |
Diameter of tumor (cm) | |
Group 1: < 2 | 26 (35.6) |
Group 2: ≥ 2 | 47 (64.4) |
Sentinel node state | |
Group 1: Negative | 71 (97.3) |
Group 2: Positive | 2 (2.7) |
Postoperative pathological type | |
Group 1: Intraductal carcinoma | 7 (9.6) |
Group 2: Infiltrating ductal carcinoma | 65 (89.0) |
Group 3: Others | 1 (1.4) |
ER State | |
Group 1: Positive | 59 (80.8) |
Group 2: Negative | 14 (19.2) |
PR State | |
Group 1: Positive | 55 (75.3) |
Group 2: Negative | 14 (19.2) |
Diameter of applicator (cm) | |
Group 1: 2.5 | 5 (6.8) |
Group 2: 3 | 36 (49.3) |
Group 3: 3.5 | 2 (2.7) |
Group 4: 4 | 1 (1.4) |
Irradiation dose (Gy) | |
Group 1: 16 | 2 (2.7) |
Group 2: 20 | 71 (97.3) |
Histological WHO Grade | |
Group 1: Grade I–II (including grade II) | 11 (15.1) |
Group 2: Above grade II | 62 (85.0) |
Chemotherapy regimen | |
Group 1: Not administered | 20 (27.4) |
Group 2: Mainly paclitaxel | 20 (27.4) |
Group 3: Mainly anthracyclines | 22 (30.1) |
Group 4: Others | 11 (15.1) |
Endocrine therapy regimen | |
Group 1: Tamoxifen | 9 (12.3) |
Group 2: Anastrozole | 28 (38.4) |
Group 3: Exemestane | 10 (13.7) |
Group 4: Not administered | 26 (35.6) |